Von Hippel-Lindau Disease via VHL Gene
Use
This test is intended for individuals with relevant clinical features who have a suspected diagnosis, or who have a family member with presumed or genetically-confirmed Von Hippel-Lindau disease. It is also useful for reproductive partners of individuals with a known pathogenic variant in the VHL gene.
Special Instructions
For ordering, sign in for standard institutional pricing and ensure use of appropriate test requisition forms, especially for prenatal or STAT testing. Additional options such as targeted family testing and other related tests can be explored post-report reception.
Limitations
The test performance characteristics have not been cleared or approved by the US Food and Drug Administration. Interpretation is dependent on quality clinical information provided.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided